78 216

Cited 15 times in

Clinical Implementation of Precision Medicine in Gastric Cancer

DC Field Value Language
dc.contributor.author정재호-
dc.date.accessioned2022-08-19T06:26:18Z-
dc.date.available2022-08-19T06:26:18Z-
dc.date.issued2019-09-
dc.identifier.issn2093-582X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189171-
dc.description.abstractGastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical treatment decisions are mostly made based on the extent of the tumor and its anatomy, such as tumor-node-metastasis staging. Recent advances in genome-wide molecular technology have enabled delineation of the molecular characteristics of GC. Based on this, efforts have been made to classify GC into molecular subtypes with distinct prognosis and therapeutic response. Simplified algorithms based on protein and RNA expressions have been proposed to reproduce the GC classification in the clinical field. Furthermore, a recent study established a single patient classifier (SPC) predicting the prognosis and chemotherapy response of resectable GC patients based on a 4-gene real-time polymerase chain reaction assay. GC patient stratification according to SPC will enable personalized therapeutic strategies in adjuvant settings. At the same time, patient-derived xenografts and patientderived organoids are now emerging as novel preclinical models for the treatment of GC. These models recapitulate the complex features of the primary tumor, which is expected to facilitate both drug development and clinical therapeutic decision making. An integrated approach applying molecular patient stratification and patient-derived models in the clinical realm is considered a turning point in precision medicine in GC.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Gastric Cancer Association-
dc.relation.isPartOfJOURNAL OF GASTRIC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleClinical Implementation of Precision Medicine in Gastric Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorJaewook Jeon-
dc.contributor.googleauthorJae-Ho Cheong-
dc.identifier.doi10.5230/jgc.2019.19.e25-
dc.contributor.localIdA03717-
dc.relation.journalcodeJ01415-
dc.identifier.eissn2093-5641-
dc.identifier.pmid31598369-
dc.subject.keywordStomach neoplasm-
dc.subject.keywordPrecision medicine-
dc.subject.keywordTumor biomarkers-
dc.subject.keywordAdjuvant chemotherapy-
dc.subject.keywordMolecular targeted therapy-
dc.contributor.alternativeNameCheong, Jae Ho-
dc.contributor.affiliatedAuthor정재호-
dc.citation.volume19-
dc.citation.number3-
dc.citation.startPage235-
dc.citation.endPage253-
dc.identifier.bibliographicCitationJOURNAL OF GASTRIC CANCER, Vol.19(3) : 235-253, 2019-09-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.